Activity of the anti-IGF-IR antibody CP-751,871 in combinatiion with docetaxel as first-line treatment for castration resistant prostate cancer in a randomized Phase II trial
De Bono JS, Petrylak DP, Calvo E, Saad F, Hudes GR, Cooney MM, Pollak MN, Agus DB, Gillessen S, Scranton J
Activity of the anti-IGF-IR antibody CP-751,871 in combinatiion with docetaxel as first-line treatment for castration resistant prostate cancer in a randomized Phase II trial